Treatment of Severe Pulmonary Blastomycosis with Oral Itraconazole: Case Report

Ralph, Edward D.; Plaxton, William R.; Sharpe, Michael D.

doi:10.1086/313459

Cited by 4 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Поскольку пациенты с очень тяжелым течением, в т. ч. с поражением ЦНС, исключались из протоко лов крупных клинических исследований, в которых сравнивались эффективность итраконазола и амфо терицина В дезоксихолата, последний остается «золотым стандартом» в лечении таких больных. Следует отметить, что описано несколько случаев достаточно тяжелого течения заболевания, при ко торых итраконазол был эффективен [63,64].…”

Section: иммунокомпетентные больныеunclassified

“…Во первых, если поражение ЦНС прогрессирует на фоне лечения амфотерицина В дезоксихолатом или впервые появляется при лече нии итраконазолом легочного или диссеминирован ного бластомикоза, но без первоначального пораже ния ЦНС, это требует смены тактики лечения [64,67,69,74]. Целесообразным, хотя и недоказанным режимом может быть комбинация липосомального амфотерицина В и флюконазола 800 мг в сутки до до стижения клинического улучшения, после чего про должают терапию флюконазолом в течение 6 мес.…”

Section: лечение больных с иммуносупрессиейunclassified

See 1 more Smart Citation

Treatment of fungal infections in adult pulmonary and critical care patients

Лимпер¹,

Нокс²,

Сарози³

et al. 2011

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

Section: иммунокомпетентные больныеunclassified

Section: лечение больных с иммуносупрессиейunclassified

Treatment of fungal infections in adult pulmonary and critical care patients

Лимпер¹,

Нокс²,

Сарози³

et al. 2011

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

Cerebral blastomycosis: a case series incorporating voriconazole in the treatment regimen

et al. 2006

View full text Add to dashboard Cite

Cerebral blastomycosis is a rarely reported disease. We report three cases of cerebral blastomycosis previously treated with standard antifungal therapy, which were subsequently successfully treated with voriconazole. The first is a 29-year-old man who initially presented with concomitant cutaneous and osseous blastomycosis; the second is a 50-year-old man who initially presented with prostatic, pulmonary and cutaneous lesions. The third patient was a 63-year-old man who presented with hemiplegia and multiple intra-cerebral blastomycomas. This report represents the first two documented relapses, in Canada, of CNS blastomycosis following treatment with itraconazole and, to our knowledge, among the first three worldwide human cases of cerebral blastomycosis treated successfully with voriconazole.

show abstract

An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients

Limper

Knox²,

Sarosi

et al. 2011

Am J Respir Crit Care Med

523

372

View full text Add to dashboard Cite

With increasing numbers of immune-compromised patients with malignancy, hematologic disease, and HIV, as well as those receiving immunosupressive drug regimens for the management of organ transplantation or autoimmune inflammatory conditions, the incidence of fungal infections has dramatically increased over recent years. Definitive diagnosis of pulmonary fungal infections has also been substantially assisted by the development of newer diagnostic methods and techniques, including the use of antigen detection, polymerase chain reaction, serologies, computed tomography and positron emission tomography scans, bronchoscopy, mediastinoscopy, and video-assisted thorascopic biopsy. At the same time, the introduction of new treatment modalities has significantly broadened options available to physicians who treat these conditions. While traditionally antifungal therapy was limited to the use of amphotericin B, flucytosine, and a handful of clinically available azole agents, current pharmacologic treatment options include potent new azole compounds with extended antifungal activity, lipid forms of amphotericin B, and newer antifungal drugs, including the echinocandins. In view of the changing treatment of pulmonary fungal infections, the American Thoracic Society convened a working group of experts in fungal infections to develop a concise clinical statement of current therapeutic options for those fungal infections of particular relevance to pulmonary and critical care practice. This document focuses on three primary areas of concern: the endemic mycoses, including histoplasmosis, sporotrichosis, blastomycosis, and coccidioidomycosis; fungal infections of special concern for immune-compromised and critically ill patients, including cryptococcosis, aspergillosis, candidiasis, and Pneumocystis pneumonia; and rare and emerging fungal infections.

show abstract

Treatment of Severe Pulmonary Blastomycosis with Oral Itraconazole: Case Report

Cited by 4 publications

References 7 publications

Treatment of fungal infections in adult pulmonary and critical care patients

Treatment of fungal infections in adult pulmonary and critical care patients

Cerebral blastomycosis: a case series incorporating voriconazole in the treatment regimen

An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients

Contact Info

Product

Resources

About